Pierre Fabre | Date: 2016-09-12
The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein:
Pierre Fabre | Date: 2015-04-30
The present invention relates to a combination comprising a hyaluronic acid or a salt thereof and a sulphated polysaccharide of which the molecular weight is between 5 and 25 kDa, which is of use in particular for combating the signs of skin ageing or for treating and healing skin wounds.
Pierre Fabre | Date: 2015-05-13
The invention relates to an association comprising a peptide containing the sequence A-Lys-Gly-His-Lys-NH_(2), wherein A is the radical corresponding to a C_(1 )to C_(18 )saturated or unsaturated fatty acid, and glyceryl laurate or one of the derivatives thereof. The invention also relates to the use thereof for stimulating hair growth.
Pierre Fabre | Date: 2016-07-21
A method for high temperature sterilization of an emulsion, in particular a dermocosmetic preparation. The method includes the steps of gradually pre-heating, performing ultra-high temperature sterilization and gradually cooling the emulsion. The emulsion is heated up to a pre-heating temperature, which is the temperature of the emulsion at the stability limit. Ultra-high temperature sterilization is performed by infusion of the pre-heated emulsion by heating the emulsion up to a sterilization temperature, maintaining the emulsion at the sterilization temperature, and cooling the emulsion under a vacuum at an end-of-sterilization temperature. The emulsion is gradually cooled with agitation to a storage temperature.
Pierre Fabre | Date: 2017-03-01
The disclosure relates to an antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The disclosure also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Pierre Fabre | Date: 2015-10-26
The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.
Pierre Fabre | Date: 2015-07-06
The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
Pierre Fabre | Date: 2016-09-07
The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FoF-01-2014 | Award Amount: 7.13M | Year: 2015
The goal of C2NET Project is the creation of cloud-enabled tools for supporting the supply network optimization of manufacturing and logistic assets based on collaborative demand, production and delivery plans. C2NET Project will provide a scalable real-time architecture, platform and software to allow the supply network partners: to master complexity and data security of the supply network, to store product, process and logistic data, to optimize the manufacturing assets by the collaborative computation of production plans, to optimize the logistics assets through efficient delivery plans and to render the complete set of supply chain management information on the any digital mobile device (PC, tablets, smartphones, ) of decision makers enabling them to monitor, visualize, control, share and collaborate. The Project results will be: i) the C2NET Data Collection Framework for IoT-based continuous data collection from supply network resources; ii) the C2NET Optimizer for the optimization of manufacturing and logistics assets of the supply network by the collaborative computation of production, replenishment and delivery plans; iii) the C2NET Collaboration Tools for providing support to the collaborative processes of the supply network, and iv) the C2NET Cloud Platform (C2NET CPL) to integrate the data module, the optimizers and the collaborative tools in the cloud. C2NET will be designed to comprehensively cover the entire supply chain considering all stages of manufacturing, distribution and sales to supply a product to market. Different actors in the supply network as plant managers, planners, carriers, shop floor workers, shop assistants or customers are potential users of the services that will be offered by C2NET. A distinguishing feature of these services is to have complete visibility and real-time status of the entire supply chain at all times looking for an optimal response to maximize both local and global benefit
Bailly C.,Pierre Fabre
Chemical Reviews | Year: 2012
Some challenges faced in the design of topoisomerase II inhibitors for cancer chemotherapy are studied. Topoisomerase II is arguably the second most abundant chromatin protein after histones. DNA topoisomerases are classified into two categories. Monomeric type I enzymes catalyze the formation of DNA single-strand breaks. Multimeric type II enzymes engender DNA double-strand breaks (DSBs). The topoisomerase II is a ubiquitous enzyme, present in both tumoral and nontumoral cells, and therefore a strict cancer specificity cannot be achieved with this type of target; more cancer-selective targets are now preferred. Topoisomerase II remains a challenging protein, and the principal difficulty at the pharmacological level has been to target specifically one isoform over the other. It is the C-terminal domain of topoisomerase II that distinguishes the two isoforms in terms of binding to DNA. DNA topoisomerase II is a molecular engineer that unravels the DNA during replication and transcription.